

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(10) International Publication Number
WO 2022/056137 A1

(43) International Publication Date
17 March 2022 (17.03.2022)

(51) International Patent Classification:

A61K 31/7004 (2006.01) A61K 47/38 (2006.01)
A61P 21/00 (2006.01)

(21) International Application Number:

PCT/US2021/049677

(22) International Filing Date:

09 September 2021 (09.09.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/076,761 10 September 2020 (10.09.2020) US

(71) Applicant: **THE CHARLOTTE MECKLENBURG HOSPITAL AUTHORITY D/B/A ATRIUM HEALTH** [US/US]; 1000 Blythe Blvd., Charlotte, North Carolina 28203 (US).

(72) Inventors: **LU, Qi Long**; c/o The Charlotte Mecklenburg Hospital, Authority D/B/A Atrium Health, 1000 Blythe Blvd., Charlotte, North Carolina 28203 (US). **WU, Bo**; c/o The Charlotte Mecklenburg Hospital, Authority D/B/A Atrium Health, 1000 Blythe Blvd., Charlotte, North Carolina 28203 (US).

(74) Agent: **CHRISTIANSEN, William** et al.; c/o Cooley LLP, 1299 Pennsylvania Avenue, NW, Suite 700, Washington, District of Columbia 20004 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(54) Title: RIBITOL TREATMENT

(57) Abstract: Provided are methods of treating a disease or disorder in a subject in need thereof and associated compositions. An effective amount of ribitol is administered, thereby restoring and/or enhancing functional glycosylation of α -DG and/or treating the disease or disorder.

WO 2022/056137 A1